Filana Therapeutics, Inc.
Key Metrics
Market Snapshot
About
Filana Therapeutics, Inc. (FLNA) is a biotechnology company based in Austin, Texas, that is best known for its clinical-stage drug development programs targeting neurodegenerative diseases, with its primary focus on Alzheimer's disease.
The company's main therapeutic candidate is simufilam, a small molecule drug undergoing a Phase 3 clinical trial for the treatment of Alzheimer's disease. This trial represents a late-stage evaluation of the compound's potential efficacy and safety. Filana Therapeutics is also developing an investigational diagnostic product called SavaDx, an early-stage program intended to detect Alzheimer's disease from a small blood sample.
Founded in 1998, the company operates in the clinical-stage biotech sector, advancing its programs through the regulatory and trial processes required to bring new treatments and diagnostics to market. Its strategy centers on addressing Alzheimer's disease through both a potential therapeutic intervention and a companion diagnostic tool. The company was formerly known as Cassava Sciences, Inc. before changing its name to Filana Therapeutics, Inc. in March 2026.